Cyclophosphamide/fludarabine/ibrutinibHepatitis-B reactivation and acquired-resistance leading to no effect: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1923卷 / 1期

关键词：

D O I：

10.1007/s40278-022-23029-y

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：166 / 166

相关论文

共 50 条

[1] Chlorambucil/ibrutinibHepatitis-B reactivation and lack of efficacy: case report
Reactions Weekly, 2023, 1965 (1) : 147 - 147
[2] IbrutinibHepatitis B reactivation: case report
Reactions Weekly, 2020, 1827 (1) : 167 - 167
[3] IbrutinibHepatitis B virus reactivation: case report
Reactions Weekly, 2018, 1729 (1) : 142 - 142
[4] Cyclophosphamide/fludarabine/rituximabHepatitis B virus reactivation: case report
Reactions Weekly, 2015, 1567 (1) : 77 - 77
[5] Cyclophosphamide/fludarabine/rituximabHepatitis B virus reactivation successfully treated with entecavir: case report
Reactions Weekly, 2010, 1290 (1) : 18 - 18
[6] Cyclophosphamide/fludarabine/rituximabIncreased ALT levels and hepatitis B virus reactivation: case report
Reactions Weekly, 2021, 1864 (1) : 125 - 125
[7] Cyclophosphamide/fludarabine/rituximabReactivation of hepatitis B virus leading to fatal acute liver failure: case report
Reactions Weekly, 2008, 1232 (1) : 13 - 13
[8] Immunosuppressants/entecavirHepatitis B reactivation and acquired drug resistance: case report
Reactions Weekly, 2022, 1902 (1) : 244 - 244
[9] Fludarabine/rituximabFatal reactivation of hepatitis B infection: case report
Reactions Weekly, 2002, 885 (1) : 9 - 9
[10] Cyclophosphamide/doxorubicin/paclitaxelHepatitis B reactivation: case report
Reactions Weekly, 2023, 1969 (1) : 134 - 134

← 1 2 3 4 5 →